文献速递区域麻醉与超声疼痛医学

鞘内阿片类药物在肾移植中的应用:一项观察性队列研究

Intrathecal Opioid Use in Kidney Transplantation: An Observational Cohort Study.
PubMed 文献 · Anesth Analg · 2023-10-06

该回顾性队列研究纳入2017年8月至2022年7月单中心1014例肾移植手术,采用IPTW比较术前鞘内阿片(均为氢吗啡酮,中位剂量100 µg)与否的结局。鞘内组术后72小时阿片需求量与疼痛评分更低,但术后恶心呕吐风险更高。

要点

  • 鞘内氢吗啡酮中位剂量100 µg可降低肾移植术后72小时阿片需求与疼痛评分。
  • 鞘内阿片组术后恶心呕吐发生率55% vs 38%,风险增加。
  • 优势与恶心呕吐风险并存,需个体化权衡。

核心结论

  • 肾移植术前鞘内阿片给药与术后72小时阿片需求量和疼痛评分降低相关,但术后恶心呕吐风险增加。

研究设计与样本

  • 回顾性队列研究,提取2017年8月1日至2022年7月31日单中心肾移植手术数据。
  • 共纳入1012例患者的1014例肾移植,411例(41%)术前接受鞘内阿片。
  • 采用逆概率治疗加权(IPTW)比较临床结局。

主要发现

  • 鞘内阿片均为氢吗啡酮,中位剂量100 µg(IQR 100-100;范围50-200)。
  • 术后72小时阿片需求量:30(0-68)vs 64(22-120)MME;IPTW几何均值比0.34(95%CI 0.26-0.43;P<.001)。
  • 总阿片量(术中加术后):45(30-75)vs 75(60-90)MME;几何均值比0.58(95%CI 0.54-0.63;P<.001)。
  • 最大疼痛评分24小时:4(2-7)vs 7(5-8),OR 0.28(95%CI 0.21-0.37;P<.001);72小时:6(4-7)vs 7(5-8),OR 0.41(95%CI 0.31-0.54;P<.001)。
  • 术后恶心呕吐:225/411(55%)vs 232/603(38%);OR 2.16(95%CI 1.63-2.86;P<.001)。

临床怎么用

  • 肾移植术前可考虑鞘内氢吗啡酮以改善术后72小时镇痛并减少阿片用量。
  • 使用鞘内阿片时应警惕术后恶心呕吐风险增加,并做好预防与处理。

局限性

  • 单中心回顾性队列设计,可能存在残余混杂。
  • 鞘内阿片均为氢吗啡酮,结果外推至其他阿片需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney transplant is the most common transplant operation performed in the United States. Although various approaches to pain management have been described, the optimal analgesic strategy remains undefined. Specifically, the role of intrathecal opioids in this patient population has not been comprehensively evaluated. METHODS: Using a retrospective cohort design, data from kidney transplant operations at a single tertiary care medical center between August 1, 2017, and July 31, 2022, were extracted. Inverse probability of treatment weighting (IPTW) was used to assess differences in clinical outcomes based on the presence or absence of intrathecal opioid administration before surgical incision. The primary outcome was total opioid exposure expressed in milligram morphine equivalents (MME) in the first 72 hours postoperatively, with secondary outcomes including total MME (intraoperative plus postoperative MME, postoperative pain scores, and the presence of postoperative nausea/vomiting [PONV], pruritus, or adverse events). RESULTS: A total of 1014 kidney transplants in 1012 unique patients were included, with 411 (41%) receiving intrathecal opioids preoperatively. Hydromorphone was the intrathecal opioid used in all cases with median dose of 100 µg (interquartile range [IQR], 100, 100; range 50-200). Subjects receiving intrathecal opioids had significantly lower postoperative opioid requirements at 72 hours (30 [0-68] vs 64 [22, 120] MME), with ratio of geometric means in the IPTW analysis (ratio of geometric means 0.34, 95% confidence interval [CI], 0.26-0.43; P < .001). Similar findings were observed for total opioids (45 [30-75] vs 75 [60-90] MME; ratio of geometric means 0.58, 95% CI, 0.54-0.63; P < .001). Maximum reported pain scores in the intrathecal group were lower at 24 hours (4 [2-7] vs 7 [5, 8]; OR, 0.28; 95% CI, 0.21-0.37 for experiencing a higher pain score with intrathecal opioids, P < .001) and 72 hours (6 [4-7] vs 7 [5-8]; OR, 0.41; 95% CI, 0.31-0.54; P < .001). Patients receiving intrathecal opioids were more likely to experience PONV (225 of 411 [55%] vs 232 of 603 [38%]; OR, 2.16; 95% CI, 1.63-2.86; P < .001). CONCLUSIONS: Intrathecal opioid administration was associated with improved pain outcomes in patients undergoing kidney transplantation, including lower opioid requirements and pain scores through 72 hours. However, this was accompanied by an increased risk of PONV.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Hofer RE, Sims CR, Dean PG, et al. Intrathecal Opioid Use in Kidney Transplantation: An Observational Cohort Study. Anesth Analg. 2023. PMID: 37801575. doi:10.1213/ANE.0000000000006665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。